US20010047023A1 - New Heterocyclic compounds for therapeutic use - Google Patents

New Heterocyclic compounds for therapeutic use Download PDF

Info

Publication number
US20010047023A1
US20010047023A1 US09/809,485 US80948501A US2001047023A1 US 20010047023 A1 US20010047023 A1 US 20010047023A1 US 80948501 A US80948501 A US 80948501A US 2001047023 A1 US2001047023 A1 US 2001047023A1
Authority
US
United States
Prior art keywords
trifluoromethyl
methylphenyl
phenyl
pyrazole
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/809,485
Other versions
US6403629B2 (en
Inventor
Atul Shrikhande
Madhukant Doshi
Shirish Mody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JB Chemicals and Pharmaceuticals Ltd
Original Assignee
JB Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JB Chemicals and Pharmaceuticals Ltd filed Critical JB Chemicals and Pharmaceuticals Ltd
Priority to US09/809,485 priority Critical patent/US6403629B2/en
Assigned to J.B. CHEMICAL AND PHARMACEUTICALS LIMITED reassignment J.B. CHEMICAL AND PHARMACEUTICALS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOSHI, MADHUKANT MANSUKHLAL, MODY, SHIRISH BHAGWANLAL, SHRIKHANDE, ATUL ANANT
Publication of US20010047023A1 publication Critical patent/US20010047023A1/en
Priority to PCT/IN2002/000036 priority patent/WO2002074235A2/en
Priority to EP02735961A priority patent/EP1377289A4/en
Priority to AU2002309243A priority patent/AU2002309243A1/en
Application granted granted Critical
Publication of US6403629B2 publication Critical patent/US6403629B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to new heterocyclic compounds of the general formula 1 and 2 for therapeutic use.
  • the invention further relates to pharmaceutical compositions containing the compounds of the general formula 1 and 2, process for preparing the same and pharmaceutically acceptable salts thereof having a selective action on inflammation and its related disorders.
  • Nonsteroidal anti-inflammatory drugs are compounds used mainly in the relief of pain, inflammation, and sometimes fever.
  • NSAIDS The combined analgesic and antiinflammatory effects of NSAIDS make them particularly useful for the symptomatic relief of painful and/or inflammatory conditions including musculoskeletal and joint disorders, such as rheumatoid arthritis, osteoarthritis, spondylo arthopathic, peri-articular and soft tissue disorder.
  • NSAIDS have shown to be useful in alleviating symptoms of inflammation and pain disorders.
  • Prostaglandins are ubiquitous fatty acid derivatives that serve as autocrine/paracrine mediators involved in many different physiological processes in addition to their well recognized role in inflammation and immune response modulation.
  • Prostaglandins elicit a variety of important and beneficial responses.
  • Among the undesirable properties of Prostaglandins is their ability to induce pain, fever, and symptoms associated with the inflammatory response.
  • NSAIDS exert their actions primarily by inhibiting the production of PGs.
  • Recent studies of inflammatory processes has led to the identification of the key enzyme cycloxygenase (Cox) that is expressed in inflammatory conditions.
  • Cox-2 enzyme cycloxygenase
  • Various studies on the identification of Cox-2 enzyme are reported:-Vane , J. R.; Nature 1994, Made, E. A. ., Smith W. L. ., Dewitt, D. L. J. Biol. Chem. 1993, 268: 6610-14
  • Cox is the first enzyme in the prostanoid biosynthetic pathway catalyzing the conversion of arachidonic acid to PGH2 as the first step in the synthesis of PGs, Prostacyclins, and Thromboxane, all of which act as important mediators of biological and inflammatory responses. Pairet, M., Engekelhardt,G; Fundam. Clin. Pharmacol 1996,10 ,1-15
  • NSAIDS cyclooxygenase-1
  • Cox-2 cyclooxygenase-2
  • NSAIDS that are highly selective inhibitors of the form cycloxygenase -2 may have less gastrointestinal toxicity, hence, interest has developed in NSAIDS that are highly selective inhibitors of Cox-2, such as Meloxicam, Nimesulide, Rofecoxib and the like.
  • NSAIDS like Diclofenac , Flufenamic acid, Ibuprofen, Indomethacin and the like, inhibit both the forms of the enzymes (Cox-1 and Cox-2) with many showing selectivity for Cox-1 enzyme.
  • Inhibition of COX -1 enzyme causes the common gastrointestinal side effects as seen in the known NSAIDS like Diclofenac, Flufenamic acid, Ibuprofen, Indomethacin and the like. All these antiinflammatory agents have shown undesirable side effects.
  • the present invention relates to new NSAIDS compounds having Diarylpyrazole ring of the general formula 1 and formula 2, their synthesis and their pharmaceutically acceptable addition salts having a antiinflammatory, antipyretic, or antibacterial activity.
  • the present invention also relates to synthesis of the intermediates (substituted diketo compounds) of the compounds of general formula 1:
  • R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-aryl sulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N, N-dial kylamido, N-alkyl-N-aryl amido, N, N-dialkylsulfamyl with the alkyl , or alkyl part of each such group containing 1-3 carbon atoms.
  • the present invention also relates to synthesis of the intermediates (substituted phenyl hydrazine hydrochloride salts) of the compounds of general formula 2:
  • R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-aryl sulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N-dialkylamido, N-alkyl-N-aryl amido, N,N-dialkylsulfamyl with the alkyl or alkyl part of each such group containing 1-3 carbon atoms.
  • the synthesis of the other compounds of formula 1 and 2 includes the conventional method of condensing the appropriate hydrochloride salt of substituted phenyl hydrazine with substituted triflurobutanedione (diketo compounds).
  • This invention also includes the preparation and purification of the intermediates of the compounds of formula 1 and 2.
  • Also included in this invention is the addition products, derivatives, salts formed from pharmaceutically acceptable acids or bases of the compounds of particular interest.
  • the salts or derivatives may be prepared by conventional methods by reacting the appropriate acid or base with the compounds of the general formula 1 and 2
  • the present invention also relates to the pharmaceutical compositions consisting of a product of the general formula 1 and 2 or its pharmaceutically acceptable salt when they exist, optionally in combination with any other pharmaceutically compatible substance which may be inert, or physiologically active.
  • compositions according to the invention may be administered in the form parenteral, oral, sublingual rectal, vaginal, topical, transdermal, ocular, or intranasal routes or as aerosol for the lungs.
  • compositions can also be administered in the form of modified release, controlled release, time released formulations and the like.
  • the term ‘parenteral’ as used herein enclose subcutaneous injection intravenous intramuscular, intrastemal injection or infusion techniques.
  • the sterile compositions includes aqueous or non aqueous solutions, suspension or emulsions.
  • the vehicles used can be selected from water, propylene glycol, vegetable oil, injectable organic esters or suitable organic solvents.
  • the other adjuvants includes wetting agents , isotonicity agents, emulsifiers and dispersants and stabilizers.
  • oral includes a composition containing the non toxic therapeutically effective amount of the compounds of formula 1 and 2 in a form suitable for oral use.
  • a composition containing the non toxic therapeutically effective amount of the compounds of formula 1 and 2 in a form suitable for oral use such as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powder or granules, emulsions syrups, elixirs caplets, chewable waffers and solutions freeze dried for oral or injectable dosage forms.
  • rectal or ‘vaginal’ includes compositions of the active component in the form of suppositories which is prepared by mixing with non irritant ingredients.
  • compositions like creams ointments, lotions, gels, solutions or suspensions are included in compositions like creams ointments, lotions, gels, solutions or suspensions.
  • optical includes compositions like installations.
  • intranasal includes compositions like drops, spray and the like.
  • transdermal includes compositions of the active component in the form of a patch.
  • the amount of the active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gms of the active ingredient compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to 95% of the total composition.
  • melting points are uncorrected, the melting points are given for the materials prepared as described , polymorphism may result in isolation of materials with different melting points in some preparations.
  • NMR data is in the form of delta ( ⁇ )values for major diagnostic protons, given in parts per million ( ppm) relative to tetramethylsilane (TMS) as internal standard determined at 300 MHz or 400 MHz using the indicated solvent.
  • IR data is in the form of absorption / cm for characteristic absorption of the compound, determined from 400 to 4000 cm using Potassium bromide (KBr) disc
  • step I of the scheme 4-(methanesulphonamido)phenylhydrazine hydrochloride is prepared by known conventional methods
  • step 2 the appropriate acetophenone is treated with the base and a ester to give the intermediate diketo compound.
  • This diketo compound is purified by recrystallisation .
  • step3 the Hydrazine hydrochloride of step 1 and diketo of step 2 is reacted in solvents for example lower aliphatic alcohols such as methanol, ethanol, Isopropanol and the like and lower aliphatic acids such as acetic acid and the like.
  • solvents for example lower aliphatic alcohols such as methanol, ethanol, Isopropanol and the like and lower aliphatic acids such as acetic acid and the like.
  • reaction conditions for diazotisation as in step 1 varies from ⁇ 10 deg C to +60 deg C
  • step 2 The general reaction time for step 2 varies from 8-40 hours and temperature conditions vary from 20 deg C to 60 deg C
  • reaction conditions for the final condensation as in step 3 varies from 20 deg C to 110 deg C and time period of 6-30 hours.
  • the recrystallisation solvents includes from lower aliphatic alcohols such as methanol, ethanol, Isopropanol and the like, lower aliphatic hydrocarbons such as hexane, heptane or diethylether or any other suitable inert solvent.
  • This intermediate was prepared from commercially available 4- Ethylacetophenone.
  • the product obtained was a liquid which was isolated from the reaction mixture by extraction with a suitable solvent like Ethylacetate. The evaporation of the solvent gave the diketo compound which was used as such for next step. Yield obtained was 66%.
  • This intermediate was prepared from commercially available 4-Methoxyacetophenone.
  • the recrystallized product was a light yellow crystalline powder. Yield obtained was 56%.
  • M.pt 57 deg C IR ( KBr) cm ⁇ 1 1255 (OCH3), 1110 (C-C), 1139 (aliphatic C ⁇ O),1195 (CF3), 1508 (C-H), 1600 (aromatic C ⁇ O)
  • This intermediate was prepared from commercially available 3,4-Dichloroacetophenone The recrystallized product was obtained in 40% yield as a cream powder.
  • This intermediate was prepared from 2,4- Dichloroacetophenone which is commercially available.
  • the product obtained was a liquid which was isolated by extraction using a suitable organic solvent like Ethylacetate. The evaporation of the solvent gave the diketo product which was used as such for the next step. The yield was 68%.
  • This intermediate was prepared from commercially available 2,4-Dimethyl acetophenone .
  • the product obtained was a liquid which was isolated from the reaction mixture by extraction with a suitable solvent like Ethyl acetate. The evaporation of the solvent gave the diketo product in 69% yield which was used as such for the next step.
  • N-[4-[5-(2-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide was prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(2-Methylphenyl)-4,4,4-trifluord-butane -1,3- dione by the process as described in
  • Example 1 Part C of Example 1 This compound was oxidized by Jones reagent as described in Example 2 to give a bright yellow colored solid in 26% yield.
  • step 1 the appropriate phenylhydrazine was obtained from the corresponding primary aromatic amine by diazotisation with sodium nitrite and decomposing the diazonium salt with sodium sulfite and precipitating the hydrazino compound as hydrochloride salt with HCl.
  • step 2 the p- Methyl acetophenone was condensed with Ethyltrifluoroacetate under alkaline conditions to give the 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione intermediate.
  • step3 the Hydrochloride of corresponding hydrazino compounds of step 1 and diketo compound of step2 is reacted in solvents for example lower aliphatic alcohols such as methanol, ethanol, isopropanol and the like and lower aliphatic acids such as acetic acid and the like.
  • solvents for example lower aliphatic alcohols such as methanol, ethanol, isopropanol and the like and lower aliphatic acids such as acetic acid and the like.
  • reaction conditions for diazotisation as in step 1 varies from ⁇ 10 deg C to +60 deg C
  • step 2 The general reaction time for step 2 varies from 8-40 hours and temperature conditions vary from 20deg C to 60deg C
  • the reactions conditions for the final condensation as in step 3 varies from 20 deg C to 110 deg C and time period of 6-30 hours.
  • the retrystallisation solvents includes from lower aliphatic alcohols such as methanol, ethanol, isopropanol and the like, lower aliphatic hydrocarbons such as hexane, heptane or Diethylether., or any other suitable inert solvent.
  • This intermediate was prepared by diazotisation of commercially available 3-Chloroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 80% yield
  • This intermediate was prepared by diazotisation of commercially available 4-Chloroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light pinkish brown powder in 72% yield
  • This intermediate was prepared by diazotisation of commercially available 2,4-Difluroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 69% yield
  • This intermediate was prepared by diazotisation of commercially available 3-Fluoroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 70% yield
  • This intermediate was prepared by diazotisation of commercially available 4-Fluroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light yellow powder in 68% yield
  • This intermediate was prepared by diazotisation of commercially available 3, 4-Dichloroaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light cream powder in 66% yield
  • This intermediate was prepared by diazotisation of commercially available 2- Fluoro- 4-methylaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a brown powder in 70% yield
  • This intermediate was prepared by diazotisation of commercially available 2-Fluoro- 5-methylaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a brown powder-in 74% yield
  • This intermediate was prepared by diazotisation of commercially available 3-Fluoro-4-Methylaniline.
  • the Hydrazine hydrochloride was recrystallized from water to give a light pinkish brown powder in 68% yield
  • test compounds of formula 1 and 2 were evaluated for anti-inflammatory activity and ulcerogenic activity.
  • Wistar rats 120-180 gms were fasted overnight and were given per oral either vehicle (1% sodium CMC in water) or a test compound.
  • the paw volume was measured using a Plethysmometer, (UGO- Basile Italy) based on the principal of water displacement.
  • the animals were then injected subcutaneously with 0.1 ml of 1% w/v of Carrageenan suspension in to the plantar tissue of the right hind paw.
  • the paw volume was measured at 0 hour and subsequently at 1 hour intervals upto 6 hours.
  • the percent increase in the paw volume was compared with the test compound and control. The difference of the average values between treated and control groups was calculated for each time interval and statistically evaluated.
  • test compounds exhibits anti-inflammatory activity comparable with known NSAIDS and these compounds also revealed mild injury which was significantly less than the ulcerogenic index of standard NSAID known to cause gastric lesions.

Abstract

A class of compounds particularly diaryl pyrazole of general formulas 1 and 2 where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N- alkylsulfamyl, N-arylsulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N-dialkylamido, N-alkyl-N-arylamido, N, N-dialkylsulfamyl with the alkyl, or alkyl part of each such group containing 1-3 carbon atoms or mixtures thereof optionally their salts when they exist, and preparation thereof.
The compounds of the present invention are antiinflammatory, antipyretic, antirheumatic, antiosteoarthritic agents with antibacterial activity.
The particular class of compounds is given below (Formula 1 and Formula 2).
Figure US20010047023A1-20011129-C00001

Description

    RELATED APPLICATION
  • This application claims priority to provisional application Ser. Nos. 60/201,343 filed on 2-5-2000 and 60/21.6,273 filed on 6-7-2000.[0001]
    • FIELD OF INVENTION
  • The present invention relates to new heterocyclic compounds of the general formula 1 and 2 for therapeutic use. [0002]
  • The invention further relates to pharmaceutical compositions containing the compounds of the general formula 1 and 2, process for preparing the same and pharmaceutically acceptable salts thereof having a selective action on inflammation and its related disorders. [0003]
    • BACKGROUND OF THE INVENTION
  • Nonsteroidal anti-inflammatory drugs (NSAIDS) are compounds used mainly in the relief of pain, inflammation, and sometimes fever. [0004]
  • The combined analgesic and antiinflammatory effects of NSAIDS make them particularly useful for the symptomatic relief of painful and/or inflammatory conditions including musculoskeletal and joint disorders, such as rheumatoid arthritis, osteoarthritis, spondylo arthopathic, peri-articular and soft tissue disorder. [0005]
  • NSAIDS have shown to be useful in alleviating symptoms of inflammation and pain disorders. Prostaglandins (PGs) are ubiquitous fatty acid derivatives that serve as autocrine/paracrine mediators involved in many different physiological processes in addition to their well recognized role in inflammation and immune response modulation. Prostaglandins elicit a variety of important and beneficial responses. Among the undesirable properties of Prostaglandins is their ability to induce pain, fever, and symptoms associated with the inflammatory response. [0006]
  • NSAIDS exert their actions primarily by inhibiting the production of PGs. Recent studies of inflammatory processes has led to the identification of the key enzyme cycloxygenase (Cox) that is expressed in inflammatory conditions. Various studies on the identification of Cox-2 enzyme are reported:-Vane , J. R.; Nature 1994, Made, E. A. ., Smith W. L. ., Dewitt, D. L. J. Biol. Chem. 1993, 268: 6610-14 [0007]
  • Cox is the first enzyme in the prostanoid biosynthetic pathway catalyzing the conversion of arachidonic acid to PGH2 as the first step in the synthesis of PGs, Prostacyclins, and Thromboxane, all of which act as important mediators of biological and inflammatory responses. Pairet, M., Engekelhardt,G; Fundam. Clin. Pharmacol 1996,10 ,1-15 [0008]
  • The discovery of second inducible isoenzyme has enabled the identification of two major isoforms of COX: the constitutive COX isoform , termed Cox-1 and the inducible isoform, termed the Cox-2 There are now various theories supporting the fact that the inducible Cox-2 enzyme is responsible for the production of inflammatory mediators. Drugs of Future 1998, 23, 598-601. [0009]
  • The commonest side effects occurring during therapy with NSAIDS are generally gastrointestinal disturbances, these are usually mild and reversible but in some patients, peptic ulcer and severe gastrointestinal bleeding have been reported. These adverse effects on the gastrointestinal tract may be associated with the inhibition of the form of cyclooxygenase-1 (Cox-1). NSAIDS that are highly selective inhibitors of the form cycloxygenase -2 ( Cox-2) may have less gastrointestinal toxicity, hence, interest has developed in NSAIDS that are highly selective inhibitors of Cox-2, such as Meloxicam, Nimesulide, Rofecoxib and the like. [0010]
  • Most widely used NSAIDS like Diclofenac , Flufenamic acid, Ibuprofen, Indomethacin and the like, inhibit both the forms of the enzymes (Cox-1 and Cox-2) with many showing selectivity for Cox-1 enzyme. [0011]
  • Inhibition of COX -1 enzyme causes the common gastrointestinal side effects as seen in the known NSAIDS like Diclofenac, Flufenamic acid, Ibuprofen, Indomethacin and the like. All these antiinflammatory agents have shown undesirable side effects. [0012]
    • OBJECT OF THE INVENTION
  • It is an object of the present invention to provide new pyrazole derivatives and their pharmaceutical compositions as well as their therapeutic uses and the processes for preparing the same. [0013]
  • At present there is a pharmacoepial dogma establishing a mandatory connection between anti-inflammatory, antipyretic, other therapeutic uses and the side effects mainly, gastrointestinal disturbances caused by the known NSAIDS. This dogma and the constant need has instigated the inventors to develop a newly synthesized anti-inflammatory compounds showing antimicrobial and antipyretic activity with less side effects. The pyrazole class has shown a promising drug like Celecoxib. The description of various pyrazole derivatives has been disclosed in U.S. Pat. No. 5,521207, J. Med. Chem. 1997, 40, 1347-1365 [0014]
  • Pyrazoles have been described for use in the treatment of inflammation U.S. Pat. No. 5,134,142 to Matsuo et al describes 1,5- diaryl pyrzoles and specifically ,1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl pyrazole, as having anti inflammatory activity. [0015]
  • In view of the extensive studies on the above derivatives, the inventors have discovered new compounds of diarylpyrazole class having more advantageous properties and the manufacturing process for the said new pyrazole derivatives fulfilling the desirable features as described herein under. [0016]
    • DESCRIPTION OF THE INVENTION
  • The present invention relates to new NSAIDS compounds having Diarylpyrazole ring of the general formula 1 and formula 2, their synthesis and their pharmaceutically acceptable addition salts having a antiinflammatory, antipyretic, or antibacterial activity. [0017]
  • The present invention also relates to synthesis of the intermediates (substituted diketo compounds) of the compounds of general formula 1: [0018]
    Figure US20010047023A1-20011129-C00002
  • where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-aryl sulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N, N-dial kylamido, N-alkyl-N-aryl amido, N, N-dialkylsulfamyl with the alkyl , or alkyl part of each such group containing 1-3 carbon atoms. [0019]
  • The following diarylpyrazole compounds of the formula 1 and their pharmaceutically acceptable salts and the corresponding appropriately substituted intermediates for condensation is given below: [0020]
  • 1) N-[4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1 -yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(4-Methylphenyl)-4,4,4-trifluorobutane -1,3-dione. [0021]
  • 1A) N-[4-[5-(4-Ethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1 -yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(4-Ethylphenyl)-4,4,4-trifluorobutane-1,3-dione [0022]
  • 1B) N-[4-[5-(4-Methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(4-Methoxyphenyl)-4,4,4-trifluorobutane-1,3-dione [0023]
  • 1C) N-[4-[5-(4-Ethoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4- (methanesulphonamido)phenylhydrazine hydrochloride and 1-(4-Ethoxyphenyl)-4,4,4-trifluorobutane-1,3-dione [0024]
  • 1D) N-[4-[5-(3,4-Dichlorophenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(3,4-Dichlorophenyl)- 4,4,4-trifluorobutane -1,3-dione [0025]
  • 1E) N-[4-[5-(2,4-Dichlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(2,4-Dichlorophenyl)- 4,4,4-trifluorobutane-1,3-dione [0026]
  • 1F) N-[4-[5-(2-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(2-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione [0027]
  • 1G) N-[4-[5-(2,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(2,4-Dimethylphenyl)-4,4,4-trifluorobutane-1,3-dione [0028]
  • 1H) N-[4-[5-(3,4-Dimethylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]phenyl]methanesulphonamide prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(3,4-Dimethylphenyl)- 4,4,4-trifluorobutane-1,3-dione [0029]
  • 1I) 4-[1-[4-(Methanesulphonamido)phenyl]-3-(trifluoromethyl)-1 H-pyrazol-5-yl]benzoic acid prepared by the oxidation of N-[4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl methanesulphonamide [0030]
  • 1J) 2-[1-[4-(Methanesulphonamido)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]benzoic acid prepared by the oxidation of N-[4-[5-(2-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide [0031]
  • The present invention also relates to synthesis of the intermediates (substituted phenyl hydrazine hydrochloride salts) of the compounds of general formula 2: [0032]
    Figure US20010047023A1-20011129-C00003
  • where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-aryl sulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N-dialkylamido, N-alkyl-N-aryl amido, N,N-dialkylsulfamyl with the alkyl or alkyl part of each such group containing 1-3 carbon atoms. [0033]
  • The following diaryl pyrazole compounds of the formula 2 and their pharmaceutically acceptable salts and the corresponding appropriately substituted intermediates for condensation are given below: [0034]
  • 2) 1-(3-Chloro4-fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 3-Chloro-4-fluorophenylhydrazine hydrochloride [0035]
  • 2A) 1-(3-Chlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 3-Chlorophenylhydrazine hydrochloride [0036]
  • 2B) 1-(4-Chlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 4-Chlorophenylhydrazine hydrochloride [0037]
  • 2C) 1-(2,4-Difluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 2,4-Difluorophenylhydrazine hydrochloride [0038]
  • 2D) 1-(3-Fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 3-Fluorophenylhydrazine hydrochloride [0039]
  • 2E) 1-(4-Fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 4-Fluorophenylhydrazine hydrochloride [0040]
  • 2F) 1-(3,4-Dichlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)4,4,4-trifluorobutane-1,3-dione with 3,4-Dichlorophenylhydrazine hydrochloride [0041]
  • 2G) 1-(2-Fluoro-4-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 2-Fluoro-4-methyl-phenylhydrazine hydrochloride [0042]
  • 2H) 1-(2-Fluoro-5-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 2-Fluoro-5-methylphenylhydrazine hydrochloride [0043]
  • 2I) 1-(3-Fluoro4-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole can be obtained by condensation of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione with 3-Fluoro4-methyl-phenylhydrazine hydrochloride [0044]
  • The synthesis of the other compounds of formula 1 and 2 includes the conventional method of condensing the appropriate hydrochloride salt of substituted phenyl hydrazine with substituted triflurobutanedione (diketo compounds). This invention also includes the preparation and purification of the intermediates of the compounds of formula 1 and 2. Also included in this invention is the addition products, derivatives, salts formed from pharmaceutically acceptable acids or bases of the compounds of particular interest. The salts or derivatives may be prepared by conventional methods by reacting the appropriate acid or base with the compounds of the general formula 1 and 2 [0045]
  • The present invention also relates to the pharmaceutical compositions consisting of a product of the general formula 1 and 2 or its pharmaceutically acceptable salt when they exist, optionally in combination with any other pharmaceutically compatible substance which may be inert, or physiologically active. [0046]
  • The compositions according to the invention may be administered in the form parenteral, oral, sublingual rectal, vaginal, topical, transdermal, ocular, or intranasal routes or as aerosol for the lungs. [0047]
  • Such compositions can also be administered in the form of modified release, controlled release, time released formulations and the like. [0048]
  • The term ‘parenteral’ as used herein enclose subcutaneous injection intravenous intramuscular, intrastemal injection or infusion techniques. The sterile compositions includes aqueous or non aqueous solutions, suspension or emulsions. The vehicles used can be selected from water, propylene glycol, vegetable oil, injectable organic esters or suitable organic solvents. The other adjuvants includes wetting agents , isotonicity agents, emulsifiers and dispersants and stabilizers. [0049]
  • The term ‘oral’ as used includes a composition containing the non toxic therapeutically effective amount of the compounds of formula 1 and 2 in a form suitable for oral use. such as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powder or granules, emulsions syrups, elixirs caplets, chewable waffers and solutions freeze dried for oral or injectable dosage forms. [0050]
  • The term ‘rectal’ or ‘vaginal’ includes compositions of the active component in the form of suppositories which is prepared by mixing with non irritant ingredients. [0051]
  • The term ‘topical’ composition includes compositions like creams ointments, lotions, gels, solutions or suspensions. [0052]
  • The term ‘ocular’ includes compositions like installations. [0053]
  • The term ‘intranasal’ includes compositions like drops, spray and the like. [0054]
  • The term ‘transdermal’ includes compositions of the active component in the form of a patch. [0055]
  • The amount of the active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gms of the active ingredient compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to 95% of the total composition. [0056]
    • GENERAL PROCESS FOR THE PREPARATION OF COMPOUNDS OF FORMULA 1 AND 2
  • The compounds of the formula 1 and 2 as described in this invention can be synthesized in a known procedure as given in the scheme below: [0057]
  • PART A: PREPARATION OF SUBSTITUTED PHENYLHYDRAZINE HYDROCHLORIDE [0058]
    Figure US20010047023A1-20011129-C00004
  • PART B: PREPARATION OF SUBSTITUTED DIKETO COMPOUNDS [0059]
    Figure US20010047023A1-20011129-C00005
  • PART C: CONDENSATION [0060]
    Figure US20010047023A1-20011129-C00006
  • The invention will now be illustrated with the aid of following non limiting examples. It should be understood , however, that the invention is not limited to the solely to the particular examples given below. It will be apparent that those skill in the art that any modifications, both to the materials and methods, may be practiced without departing from the purpose and interest of this invention [0061]
  • a) all operations carried out at room temperature or ambient temperature were in the range of 18 to 25 degree C. [0062]
  • b) evaporation of the solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals;4.5-30mm Hg)with a bath temperature of upto 60 degree C. [0063]
  • c) the course of the reaction was monitored by thin layer chromatography (TLC) and reaction times are given for illustration only. [0064]
  • d) melting points are uncorrected, the melting points are given for the materials prepared as described , polymorphism may result in isolation of materials with different melting points in some preparations. [0065]
  • e) the structure and purity of all final products were assured by at least one of the following techniques: TLC, NMR(nuclear magnetic resonance)spectroscopy, IR(lnfrared spectroscopy), or microanalytical data. [0066]
  • f) yields are given for illustration only. [0067]
  • g) when given , NMR data is in the form of delta (δ)values for major diagnostic protons, given in parts per million ( ppm) relative to tetramethylsilane (TMS) as internal standard determined at 300 MHz or 400 MHz using the indicated solvent. [0068]
  • h) When given, IR data is in the form of absorption / cm for characteristic absorption of the compound, determined from 400 to 4000 cm using Potassium bromide (KBr) disc [0069]
  • i) chemical symbols have their usual meanings ; the following abbreviations have also been used: v( volume ), w(weight), B.P.( boiling point), M.pt.(melting point) , L(liters), ml(milliliters),gms(grams), mg(milligrams) , mol (moles), mmol( millimoles) eq ( equivalents) deg C (degree centigrade), conc. HCI( concentrated hydrochloric acid) [0070]
    • GENERAL PROCESS FOR THE PREPARATION OF COMPOUNDS OF FORMULA I
  • In the step I of the scheme, 4-(methanesulphonamido)phenylhydrazine hydrochloride is prepared by known conventional methods [0071]
  • In the step 2,the appropriate acetophenone is treated with the base and a ester to give the intermediate diketo compound. This diketo compound is purified by recrystallisation . [0072]
  • In the step3, the Hydrazine hydrochloride of step 1 and diketo of step 2 is reacted in solvents for example lower aliphatic alcohols such as methanol, ethanol, Isopropanol and the like and lower aliphatic acids such as acetic acid and the like. [0073]
  • The reaction conditions for diazotisation as in step 1 varies from −10 deg C to +60 deg C [0074]
  • The general reaction time for step 2 varies from 8-40 hours and temperature conditions vary from 20 deg C to 60 deg C [0075]
  • The reaction conditions for the final condensation as in step 3 varies from 20 deg C to 110 deg C and time period of 6-30 hours. [0076]
  • The recrystallisation solvents includes from lower aliphatic alcohols such as methanol, ethanol, Isopropanol and the like, lower aliphatic hydrocarbons such as hexane, heptane or diethylether or any other suitable inert solvent.[0077]
    • EXAMPLE—1
  • Preparation of N-[4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0078]
    Figure US20010047023A1-20011129-C00007
    • PART A
  • Preparation of 4-(Methanesulphonamido)Phenylhydrazine Hydrochloride [0079]
  • 4-(methanesulphonamido)aniline (M.pt :116-118 deg C) was prepared from p-nitroaniline and methanesulphonyl chloride in presence of a base like N,N-dimethylaniline. The resulting 4-(methanesulphonamido)nitrobenzene (M.pt: 180-182 deg C) was then reduced with sodium dithionite under alkaline conditions. [0080]
  • In a 500 ml round bottom flask provided with efficient stirring and external cooling arrangement, 119 ml (1.19 mol) of conc.HCI was cooled to below 5 deg C and 88 gms(0.47 mol) 4-(methanesulphonamido)aniline was added. The hydrochloride thus precipitated was then diazotised below 0 deg C with 33.4 gms (0.48 mol)sodium nitrite dissolved in 50 ml water and the resulting diazonium salt was decomposed with 220 gms (1.15mol)sodium metabisulphite in 500 ml water. 4-(methanesulphonamido)phenylhydrazine hydrochloride thus precipitated within 30 mins, was filtered and recrystallized from water. The dried product was 76 gms ( yield 68%). M.pt decomposed at 240-242 deg C . IR (KBr) cm−1 3257, 1606 ( NH), 1512 (C═C ),1305 (—SO2NH—), 1127( C═S) [0081]
    • PART B
  • Preparation of 1-(4-Methylphenyl)4,4,4-Trifluorobutane-1,3-Dione [0082]
  • 125 gms (0.93 mol) of p-Methylacetophenone was dissolved in 250 ml Methanol (anhydrous) and 270 ml of Sodium Methoxide (25% in methanol) was added slowly maintaining the temperature below 30 deg C. The reaction mixture was further diluted with 250 ml Methanol and 128 ml of Ethyltrifluoroacetate(1.0 mol) was added in 4 lots with a in—between stirring period of 5 hours. The reaction was stirred at 20 -30 deg C for 16 hours. The reaction mixture was concentrated under vacuum below 40 deg C to 50% and then poured over mixture of 150 ml concentrated Hydrochloric acid and 200 gms ice. The mixture was stirred below 5 deg C for 2 hours and filtered . the product was washed with water till neutral pH and suck dried under vacuum 0.25 gms of p-Methylacetophenone was recovered from the filtrate. The 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione was dried under vacuum to give III gms off white crystalline product.( 65%) This was further recrystallized from Isopropanol to give 90 gms of white crystals. M.pt 50-52 deg C. IR KBr cm−1 1064 (C-C), 1147 (C═O), 1199 (CF3), 1458 (C-H), 1608 (aromatic C═O) [0083]
    • PART C
  • Preparation of N-[4-5-(4-Methylphenyl)-3-Trifluoromethyl)-1H-Pyrazol-1-YL]Phenyl]Methanesulphonamide. [0084]
  • 15 gms (0.065 mol) of 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione and 35 gms (0.15 mol) of 4-(methanesulphonamido)phenylhydrazine hydrochloride was refluxed in 150 ml anhydrous glacial acetic acid for 36 hours along with continuous monitoring of the reaction by TLC and then cooled to below 20 deg C and filtered .The residue was washed with hot water till neutral pH. The crude product (16 gms)was recrystallized from Methanol or Methanol and Isopropanol mixture to give 12 gms (46%) bright orange color product (M.pt 186 deg C) .The purity was 99.8% by HPLC. Chilling of the mother liquor gave further 3 gms of 99.0% purity by HPLC. [0085]
  • 1H NMR CDCl3 ( 300 MHz) :2.1 ( s, 1H , 2.4 (s, 3H), 3.0 ( s, 3H), 7.26 (m, 2H), 7.42 (m, 4H), 7.52 (m, 2H), 9.0 (s, 1H). IR ( KBr) cm−1 3251 (NH), 1691 (—C═NH), 1525 (C═C), 1481 (CH3), 1325 (Ar—NH—Ar), 1257 (CF3), 1186 (—SO2NH2—), 1141 (C-N). [0086]
  • The following compounds (examples 1A-a to 1H-a) was obtained according to procedures similar to that exemplified in PART B of Example 1. [0087]
  • The appropriate acetophenones were used for the preparation of the diketo intermediates and recrystallized in the similar manner as above: [0088]
  • 1A-a) 1-(4-Ethylphenyl)-4,4,4-trifluorobutane-1,3-dione [0089]
  • This intermediate was prepared from commercially available 4- Ethylacetophenone. The product obtained was a liquid which was isolated from the reaction mixture by extraction with a suitable solvent like Ethylacetate. The evaporation of the solvent gave the diketo compound which was used as such for next step. Yield obtained was 66%. IR (KBr) cm−1 1228 (C-C), 1149 (aliphatic C═O), 1188 (CF3),1512 (CH3), 1328(aromatic C═O) [0090]
  • 1B-a) 1-(4-Methoxyphenyl)-4,4,4-trifluorobutane-1,3-dione [0091]
  • This intermediate was prepared from commercially available 4-Methoxyacetophenone. The recrystallized product was a light yellow crystalline powder. Yield obtained was 56%. M.pt: 57 deg C IR ( KBr) cm−1 1255 (OCH3), 1110 (C-C), 1139 (aliphatic C═O),1195 (CF3), 1508 (C-H), 1600 (aromatic C═O) [0092]
  • 1C-a) 1 -(4-Ethoxyphenyl)-4,4,4-trifluorobutane-1,3-dione [0093]
  • This intermediate was obtained from commercially available 4- Ethoxyacetophenone .The recrystallized product was obtained in 48% yield as creamish white crystals. M.pt: 54 deg C IR (KBr) cm−1 1271 (C-O-C), 1114 (C-C), 1143 (aliphatic C═O), 1182 (CF3), 1560 (C-H),1604 (aromatic C═O) [0094]
  • 1D-a) 1-(3,4-Dichlorophenyl)-4,4,4-trifluorobutane-1,3-dione [0095]
  • This intermediate was prepared from commercially available 3,4-Dichloroacetophenone The recrystallized product was obtained in 40% yield as a cream powder. M.pt:40deg C IR (KBr) cm−1 1550 (C-C), 1149 (aliphatic C═O ), 1072 (CF3), 1469(C-H), 1593 (aromatic C═O), 802 (C-Cl) [0096]
  • 1E-a) 1-(2,4-Dichlorophenyl)-4,4,4-trifluorobutane-1,3 -dione [0097]
  • This intermediate was prepared from 2,4- Dichloroacetophenone which is commercially available. The product obtained was a liquid which was isolated by extraction using a suitable organic solvent like Ethylacetate. The evaporation of the solvent gave the diketo product which was used as such for the next step. The yield was 68%. IR (KBr) cm−1 1551 (C-C), 1150 (aliphatic C═O), 1120 (CF3), 1480(C-H), 1608 (aromatic C═O), 810 (C-Cl) [0098]
  • 1F-a) 1-(2-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione [0099]
  • This intermediate was prepared from commercially available 2- methylacetophenone. The product obtained was a liquid which was isolated from the reaction mixture by extraction with a suitable solvent like Ethyl acetate. The evaporation of the solvent gave the diketo product in 64% yield which was used as such for the next step. IR (KBr) cm−1 at 1147 (aliphatic C═O), 1199 (CF3 ), 1458 (C-H) 1608 (aromatic C═O) [0100]
  • 1G-a) 1-(2,4-Dimethylphenyl)-4,4,4-trifluorobutane-1,3-dione [0101]
  • This intermediate was prepared from commercially available 2,4-Dimethyl acetophenone . The product obtained was a liquid which was isolated from the reaction mixture by extraction with a suitable solvent like Ethyl acetate. The evaporation of the solvent gave the diketo product in 69% yield which was used as such for the next step. IR (KBr) cm−1 1170 (aliphatic C═O), 1182 (CF3 ),1458 (C-H), 1608 (aromatic C═O) [0102]
  • 1H-a) 1-(3,4-Dimethylphenyl)-4,4,4-trifluorobutane-1,3-dione [0103]
  • This intermediate was prepared from commercially available 3,4-dimethylacetophenone . The recrystallized product was obtained in 48% yield as a pale cream solid. M.pt: 110 deg C IR (KBr)cm−1 1093 (C-C), 1170 (aliphatic C═O ), 1182 (CF3 ),1 458 (C-H), 1608 (aromatic C═O) [0104]
  • The following compounds (examples 1A to 1H) was prepared in the similar procedure as exemplified in the Part C of example 1 using the appropriate diketo compounds [0105]
  • 1A) N-[4-[5-(4-Ethylphenyl)-3-trifluoromethyl)-1 H-pyrazol-1 -yl]phenyl]methanesulphonamide. [0106]
  • Yield: 28% A dark orange powder. M.pt: 189 deg C IR (KBr) cm−1 3261 (NH), 1697 (—C═NH), 1512 (C═C), 1402 (CH3) 1371 (Ar—NH—Ar), 1328 (CF3) 1186 (—SO2NH2), 1147 (C—N) Purity by HPLC: 99.5% [0107]
  • 1B) N-[4-[5-(4-Methoxyphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. Yield 56% A dark yellow crystalline powder. M.pt: 187 deg C IR (KBr) cm−1 3251 (NH), 1701 (—C═NH), 1510 (C=C), 1336 (Ar—NH—Ar) 1153 (CF3), 1191 (SO2NH2), 1249 (OCH3) Purity by HPLC: 98.96% [0108]
  • C) N-[4-[5-(4-Ethoxyphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0109]
  • Yield: 48% A dark yellow crystalline powder. M.pt: 164 deg C IR (KBr) cm−1 3340 (NH), 1697 (—C═NH), 1512 (C═C), 1253 ( OCH3) , 1325(Ar—NH—Ar), 1151 (CF3),1220 (SO2NH2) Purity by HPLC: 99.46% [0110]
  • 1D) N-[4-[5-(3,4-Dichlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0111]
  • Yield: 50% A dark orange yellow powder. M.pt: 186 deg C IR (KBr) cm−1 3276 (NH), 1701 (C═NH), 1510 (C═C), 1371( Ar—NH—Ar), 1226 (CF3), 1195 (SO2NH2) 1145 (C—N), 815 (C-Cl) Purity by HPLC : 98.74% [0112]
  • 1E) N-[4-[5-(2,4-Dichlorophenyl)--trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0113]
  • Yield: 28% A dark yellow powder M.pt: 162 deg C IR (KBr) cm−1 3278 (NH), 1714 (—C═NH), 1510 (C═C), 1375(Ar—NH—Ar), 1222 (CF3) 1195 (SO2NH2),1147 ( C—N), 995 ( C-Cl) Purity by HPLC: 99.6% [0114]
  • 1F) N-[4-[5-(2-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-1yl]phenyl]methanesuiphonamide [0115]
  • Yield: 30% A yellow crystalline powder M.pt: 175 deg C Purity by HPLC: 98.5% IR ( KBr) /cm : 3267( N-H), 1703 (lmine C=NH), 1510 ( CH3), 1328 (Ar—NH—Ar) 1244 (CF3),1190 (SO2NH2),1157 (C—N) [0116]
  • 1G) N-[4-[5-(2,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0117]
  • Yield: 45% A bright yellow color product. M.pt: 152 deg C IR (KBr) cm−1 3278 (NH), 1705 (—C=NH), 1512 (C═C), 1384 (CH3) 1332(Ar—NH—Ar), 1224 ( CF3) 1191 (SO2NH2),1153 ( C-N) Purity by HPLC: 99.0% [0118]
  • 1H) N-[4-[5-(3,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide. [0119]
  • Yield: 36% A bright red color powder M.pt:175 deg C IR (KBr) cm−1 3240 (NH), 1701(—C═NH ),1514 (C═C), 1467 (CH3), 1330(Ar—NH—Ar), 1251 (CF3),1186 (SO2NH2),1153 (C—N) Purity by HPLC: 99.3% [0120]
  • 1I) Preparation of 4-[4-(Methanesulphonamido)phenyl]-3-(trifluoromethyl)-1H- pyrazol-5-yl]benzoic acid. [0121]
  • A solution of 3 gms of N-[4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide in 10 ml Acetone was stirred at room temperature. Jones reagent ( about 8 ml ) was added dropwise maintaining the room temperature, till the orange color of Jones reagent persisted. The reaction was stirred at room temperature for 6 hours and monitored by TLC. The reaction mixture was concentrated under vacuum and the residue was extracted using a suitable solvent such as Ethylacetate and this extract was washed with water and brine . The organic layer was dried over sodium sulfate and evaporated to give a brown colored product ( 3 gms) The crude product was recrystallized from Isopropanol to give a pale brown product. M.pt: 168-70 deg C [0122]
  • 1J) 2-[1 -[4-(Methanesulphonamido)phenyl]-3-(trifluoromethyl)-1 H-pyrazol-5-yl]benzoic acid. [0123]
  • N-[4-[5-(2-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide was prepared by condensation of 4-(methanesulphonamido)phenylhydrazine hydrochloride and 1-(2-Methylphenyl)-4,4,4-trifluord-butane -1,3- dione by the process as described in [0124]
  • Part C of Example 1 This compound was oxidized by Jones reagent as described in Example 2 to give a bright yellow colored solid in 26% yield. [0125]
  • M.pt :164-166 deg C [0126]
    • GENERAL PROCESS FOR THE PREPARATION OF THE COMPOUNDS OF FORMULA 2
  • In the step 1, the appropriate phenylhydrazine was obtained from the corresponding primary aromatic amine by diazotisation with sodium nitrite and decomposing the diazonium salt with sodium sulfite and precipitating the hydrazino compound as hydrochloride salt with HCl. [0127]
  • In the step 2, the p- Methyl acetophenone was condensed with Ethyltrifluoroacetate under alkaline conditions to give the 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione intermediate. [0128]
  • In the step3, the Hydrochloride of corresponding hydrazino compounds of step 1 and diketo compound of step2 is reacted in solvents for example lower aliphatic alcohols such as methanol, ethanol, isopropanol and the like and lower aliphatic acids such as acetic acid and the like. [0129]
  • The reaction conditions for diazotisation as in step 1 varies from −10 deg C to +60 deg C [0130]
  • The general reaction time for step 2 varies from 8-40 hours and temperature conditions vary from 20deg C to 60deg C [0131]
  • The reactions conditions for the final condensation as in step 3 varies from 20 deg C to 110 deg C and time period of 6-30 hours. [0132]
  • The retrystallisation solvents includes from lower aliphatic alcohols such as methanol, ethanol, isopropanol and the like, lower aliphatic hydrocarbons such as hexane, heptane or Diethylether., or any other suitable inert solvent. [0133]
    • EXAMPLE—2
  • Preparation of 1-(3-Chloro4-Flurophenyl)-5-(4-Methylphenyl)-3-(Trifluoromethyl)Pyrazole. [0134]
    Figure US20010047023A1-20011129-C00008
    • PART A
  • Preparation of 3-Chloro-4-Fluorophenylhydrazine Hydrochloride [0135]
  • In a 500 ml round bottom flask provided with efficient stirring and external cooling arrangement, 51 ml (0.5 mole) of conc. HCl was cooled to below 5 deg C and 25 gms (0.13 mole) 3-chloro-4-fluoroaniline was added. The hydrochloride thus precipitated was then diazotised below 0 deg C with 12 gms (0.17 mole)sodium nitrite and the resulting diazonium salt was decomposed with 100 gms ( 0.79 mole)sodium sulphite and 12 ml caustic lye. The reaction mixture was filtered to remove impurities.225 ml conc. HCI was added and stirred well and allowed to stand overnight. The 3-chloro-4-fluorophenylhydrazine hydrochloride thus precipitated was filtered and recrystallized from water. The dried product was 18 gms ( yield 69%) M.pt: decomposed at 193 deg C. IR (KBr) cm−1 2939 and 2690(NH), 1506 (C═C),1114 (C-F), 744( C-Cl) [0136]
    • PART B
  • Preparation of 1- (4- Methylphenyl) -4,4,4-Trifluorobutane -1,3 -Dione [0137]
  • The preparation is described in Part B of example 1 [0138]
    • PART C
  • Preparation of 1-(3-Chloro4-Flurophenyl)-5-(4-Methylphenyl)-3-(Trifluoromethyl)Pyrazole. [0139]
  • 15 gms ( 0.093 mole) of 3-chloro-4-fluorophenylhydrazine hydrochloride of Part A and 11 gms ( 0.048 mole) of 1-(4-Methylphenyl)-4,4,4-trifluorobutane - 1,3- dione of Part B as given in example 1 was refluxed in 100 ml glacial acetic acid for 36 hours and then cooled to below 15 deg C and filtered . The residue was washed with hot water till neutral pH. The crude product ( 17 gms) was recrystallized from Methanol to give 10 gms ( 58% yield) M.pt: 77 deg C . The purity was 99.8% by HPLC IR (KBr) cm−1 at 1500 (C═C), 1470 (—C=NH ) 1242 (CF3),1222(C-F), 1157 and 1128 (C-N), 808 (C-Cl) [0140]
  • The following compounds ( examples 2A -a to 21 -a) was obtained according to procedures similar to that exemplified in PART A of Example 3. The appropriate aniline were used for the preparation of the phenylhydrazine hydrochloride intermediates and recrystallized in the similar manner as above: [0141]
  • 2A-a) 3-Chlorophenylhydrazine hydrochloride [0142]
  • This intermediate was prepared by diazotisation of commercially available 3-Chloroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 80% yield [0143]
  • M.pt: 215 deg C decomposes [0144]
  • IR (KBr) cm−1 at 3219 and 3006 (NH), 1602 (N-N), 1500 (C═C), 779(C-CI) [0145]
  • 2B-a) 4- Chlorophenylhydrazinehydrochloride [0146]
  • This intermediate was prepared by diazotisation of commercially available 4-Chloroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light pinkish brown powder in 72% yield [0147]
  • M.pt: 205 deg C decomposes [0148]
  • IR (KBr) cm−1 at 3215 and 2989( NH) [0149]
  • 1585 (N-N), 1496 ( C═C ), 648( C-Cl) [0150]
  • 2C-a) 2,4- Difluorophenylhydrazine hydrochloride [0151]
  • This intermediate was prepared by diazotisation of commercially available 2,4-Difluroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 69% yield [0152]
  • M.pt: 215 deg C decomposes [0153]
  • IR (KBr) cm−1 2923 and 2667( NH), 1618 (NH), 1504 (aromatic C═C), [0154]
  • 715 (C-Cl), 1286, 1099 (C-F) [0155]
  • 2D-a) 3- fluorophenylhydrazine hydrochloride [0156]
  • This intermediate was prepared by diazotisation of commercially available 3-Fluoroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light brown powder in 70% yield [0157]
  • M.pt: 237 deg C decomposes [0158]
  • IR (KBr) cm−1 3448 and 3199( NH), 1581 (NH), 1496 (C═C), 675(C-CI), 1151,1263 (C-F) [0159]
  • 2E-a) 4- fluorophenylhydrazine hydrochloride [0160]
  • This intermediate was prepared by diazotisation of commercially available 4-Fluroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light yellow powder in 68% yield [0161]
  • M.pt: 180 deg C decomposes [0162]
  • IR (KBr) cm−1 3448 (NH), 1514 (NH), 1232,1066 (C-F) [0163]
  • b [0164] 2F-a) 3,4- Dichlorophenylhydrazine hydrochloride
  • This intermediate was prepared by diazotisation of commercially available 3, 4-Dichloroaniline. The Hydrazine hydrochloride was recrystallized from water to give a light cream powder in 66% yield [0165]
  • M.pt: 185 deg C decomposes [0166]
  • IR (KBr) cm−1 3618 and 3209( NH), 1614 (NH), 1475 (C═C), 671 (C-Cl) [0167]
  • 2G-a) 2-Fluoro-4-methylphenylhydrazine hydrochloride [0168]
  • This intermediate was prepared by diazotisation of commercially available 2- Fluoro- 4-methylaniline. The Hydrazine hydrochloride was recrystallized from water to give a brown powder in 70% yield [0169]
  • M.pt: Above 300 deg C [0170]
  • IR (KBr) cm−1 3450( NH), 1637 (NH), 1137 (C-F) [0171]
  • 2H-a) 2-Fluoro-5-Methylphenylhydrazine hydrochloride [0172]
  • This intermediate was prepared by diazotisation of commercially available 2-Fluoro- 5-methylaniline. The Hydrazine hydrochloride was recrystallized from water to give a brown powder-in 74% yield [0173]
  • M.pt: Above 300 deg C [0174]
  • IR (KBr) cm−1 3427( NH), 1617 (NH), 1150 (C-F) [0175]
  • 21-a) 3-Fluoro-4-Methylphenylhydrazine hydrochloride [0176]
  • This intermediate was prepared by diazotisation of commercially available 3-Fluoro-4-Methylaniline. The Hydrazine hydrochloride was recrystallized from water to give a light pinkish brown powder in 68% yield [0177]
  • M.pt: 195 deg C decomposes [0178]
  • IR (KBr) cm−1 3436 (NH), 1583 (NH), 1508 (C═C), 640 (C-Cl), 1232,1097 (C-F) [0179]
  • The following compounds (examples 2A to 2I) was prepared in the similar procedure as exemplified in the Part C of example 3 using the appropriate hydrochloride salt of hydrazino compounds: [0180]
  • 2 A) 1-(3-CHLOROPHENYL)-5-(4-METHYLPHENYL)-3- (TRIFLUOROMETHYL) PYRAZOLE. [0181]
  • Yield: 42% [0182]
  • A white crystalline powder. [0183]
  • M.pt: 45 deg C [0184]
  • Purity by HPLC: 98.86% [0185]
  • IR (KBr) cm−1 at 1595(C═C), 1471 (—C═NH), 1232 (CF3), 1157 and 1128 (C—N),806(C-CI) [0186]
  • 2B) 1-(4-CHLOROPHENYL)-5-(4-METHYLPHENYL)-3- (TRIFLUOROMETHYL) PYRAZOLE. [0187]
  • Yield: 57% [0188]
  • A white crystalline powder [0189]
  • M.pt: 126 deg C [0190]
  • Purity by HPLC: 97.9% [0191]
  • IR (KBr) cm−1 at 1496(C═C), 1471 (—C═NH ) 1234 (CF3), 1159 and 1134 (C—N),806(C-Cl) [0192]
  • 2C) 1-(2,4-DIFLUOROPHENYL)-5-(4- METHYLPHENYL)-3-(TRIFLUOROMETHYL) PYRAZOLE [0193]
  • Yield: 36% [0194]
  • A creamish white crystalline powder. [0195]
  • M.pt: 83 deg C [0196]
  • Purity by HPLC: 99.95% [0197]
  • IR (KBr).cm−1 shows absorption /cm at 1509 (C═C), 1471 (—C═NH) 1246 (CF3) 1093(C-F), 1134(C—N) [0198]
  • 2D) 1 -(3-FLUOROPHENYL)-5-(4-METHYLPHENYL) -3- (TRIFLUOROMETHYL) PYRAZOLE. [0199]
  • Yield: 38% [0200]
  • A white crystalline powder. [0201]
  • M.pt: 58 deg C [0202]
  • Purity by HPLC: 97.96% [0203]
  • IR (KBr) cm−1 at 1602(C═C), 1471 (—C═NH ) 1244 (CF3), 1161 and 1128 (C—N) [0204]
  • 2E) 1-(4-FLUOROPHENYL)-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL) PYRAZOLE. [0205]
  • Yield: 6% [0206]
  • A brown solid. [0207]
  • M.pt: 68-70deg C [0208]
  • IR (KBr) cm−1 at 1604 (C═C), 1477 (—C═NH ) 1248 (CF3), 1159 and 1130 (C—N), [0209]
  • 2F) 1-(3,4-DICHLOROPHENYL)-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-PYRAZOLE. [0210]
  • Yield: 31% [0211]
  • A light brown colored powder. [0212]
  • M.pt: 94 deg C [0213]
  • Purity by HPLC: 98.86% [0214]
  • IR (KBr) cm−1 at 1591(C═C), 1471 (—C═NH ) 1232 (CF3), 1159 and 1136 (C—N), 817(C-Cl) [0215]
  • 2G) 1-(2-FLUORO4-METHYLPHENYL)-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE. [0216]
  • Yield: 80% [0217]
  • A pale brown colored liquid [0218]
  • B.P.: 145 deg C [0219]
  • Purity by HPLC: 99.6% [0220]
  • IR (KBr) cm−1 at 1580(C═C), 1468 (—C═NH ) 1228 (CF3), 1145 and 1139 (C—N) [0221]
  • 2H) 1-(2-FLUORO-5-METHYLPHENYL)-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE. [0222]
  • Yield: 40% [0223]
  • A light brown colored product [0224]
  • M.pt: 45 deg C [0225]
  • IR (KBr) cm−1 at 1600 (C═C), 1470 (—C═NH ) 1230 (CF3) , 1150 and 1125 (C—N), [0226]
  • 2I) 1-(3-FLUORO4-METHYLPHENYL)-5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE. [0227]
  • Yield: 80% [0228]
  • A brown colored viscous oil. [0229]
  • B.P.: 144 deg C [0230]
  • IR (KBr) cm−1 at 1595(C═C), 1471 (—C═NH ) 1232 (CF3), 1157 and 1128 (C—N), [0231]
    • BIOLOGICAL EVALUATION
  • The test compounds of formula 1 and 2 were evaluated for anti-inflammatory activity and ulcerogenic activity. [0232]
  • Wistar rats ( 120-180 gms ) were fasted overnight and were given per oral either vehicle (1% sodium CMC in water) or a test compound. The paw volume was measured using a Plethysmometer, (UGO- Basile Italy) based on the principal of water displacement. The animals were then injected subcutaneously with 0.1 ml of 1% w/v of Carrageenan suspension in to the plantar tissue of the right hind paw. The paw volume was measured at 0 hour and subsequently at 1 hour intervals upto 6 hours. The percent increase in the paw volume was compared with the test compound and control. The difference of the average values between treated and control groups was calculated for each time interval and statistically evaluated. The animals were sacrificed and the stomach of each animal was removed, a longitudinal incision along the greater curvature was made and the presence and absence of gastric irritation was determined. All the treatment groups were coded to eliminate observer's bias. The results indicate that some of the test compounds exhibits anti-inflammatory activity comparable with known NSAIDS and these compounds also revealed mild injury which was significantly less than the ulcerogenic index of standard NSAID known to cause gastric lesions. [0233]
  • It is to be understood that various modifications or changes that may be made to that described herein above by those of ordinary skill in the art are also contemplated by the present invention and are to be included within the spirit and purview of this application and the following claims: [0234]

Claims (12)

We claim:
1. A compound of general formula 1, and pharmaceutically acceptable salts there of where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-arylsulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N- dialkylamido, N-alkyl-N-arylamido, N,N- dialkylsulfamyl with the alkyl, or alkyl part of each such group containing 1-3 carbon atoms for the treatment of inflammation and other related disorders and also the preparation of the same.
Figure US20010047023A1-20011129-C00009
2. A compound as claimed in
claim 1
, is preferably selected from:
i) N-[4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methane sulphonamide.
ii) N-[4-[5-(4-Ethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methane sulphonamide.
iii) N-[4-[5-(4-Methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
iv) N-[4-[5-(4-Ethoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
v) N-[4-[5-(3,4-Dichlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
vi) N-[4-[5-(2,4-Dichlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
vii) N-[4-[5-(2-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol -1-yl]phenyl]methanesulphonamide.
viii) N-[4-[5-(2,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
ix) N-[4-[5-(3,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
x) 4-[1-[4-(Methanesulphonylamido)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]benzoic acid.
xi) 2-[1-[4-(Methanesulphonylamido)phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]benzoic acid.
3. A compound of general formula 2, and pharmaceutically acceptable salts thereof where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N-alkylsulfamyl, N-arylsulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N- dialkylamido, N- alkyl-N-arylamido, N,N-dialkylsulfamyl with the alkyl , or alkyl part of each such group containing 1-3 carbon atoms for the treatment of inflammation and other related disorders and also the process for the preparation of the same.
Figure US20010047023A1-20011129-C00010
4. A compound as claimed in
claim 3
, is preferably selected from:
i) 1-(3-Chloro-4-fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
ii) 1-(3-Chlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole
iii) 1-(4-Chlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
iv) 1-(2,4-Difluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
v) 1-(3-Fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
vi) 1-(4-Fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
vii) 1-(3,4-Dichlorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
viii) 1-(2-Fluoro-4-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
ix) 1-(2-Fluoro-5-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
x) 1-(3-Fluoro4-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
5. A pharmaceutical composition or a formulation or any other drug delivery system comprising a pharmaceutically acceptable carrier or diluent containing a therapeutically effective amount of the compound as claimed in
claim 1
 and
claim 3
, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition for treating the inflammatory conditions susceptible to treatment with NSAID agent comprising, a nontoxic therapeutically effective amount of a compound as claimed in
claim 1
 and
3
 and a pharmaceutically acceptable carrier or a diluent or a prodrug thereof in association with a further analgesic medicament.
7. A pharmaceutical composition as claimed in
claim 6
, in a form of parenteral, oral, sublingual, rectal, vaginal, topical, transdermal, ocular, intranasal routes or as aerosol.
8. A process for preparation of the compounds as claimed in
claim 1
 and
claim 3
, and its its intermediates as described herein in the specification.
9. The method for treatment or prevention of inflammation and associated disorder or any other illness in a patient, which comprises administering a therapeutically effective amount of the compound of
claim 1
 and
claim 3
 or a pharmaceutical salt thereof.
10. A method of purification of the key intermediates of the compounds of claim I and 3.
11. A compound of
claim 1
, is selected from
i) N-[4-[5-(2,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methanesulphonamide.
12. A compound of
claim 3
, is selected from:
i) 1-(3-Chloro4-fluorophenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole
ii) 1-(2-fluoro-4-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)pyrazole.
US09/809,485 2000-05-02 2001-03-15 Heterocyclic compounds for therapeutic use Expired - Fee Related US6403629B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/809,485 US6403629B2 (en) 2000-05-02 2001-03-15 Heterocyclic compounds for therapeutic use
PCT/IN2002/000036 WO2002074235A2 (en) 2001-03-15 2002-03-08 Heterocyclic compounds for therapeutic use
EP02735961A EP1377289A4 (en) 2001-03-15 2002-03-08 Heterocyclic compounds for therapeutic use
AU2002309243A AU2002309243A1 (en) 2001-03-15 2002-03-08 Heterocyclic compounds for therapeutic use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20134300P 2000-05-02 2000-05-02
US21627300P 2000-07-06 2000-07-06
US09/809,485 US6403629B2 (en) 2000-05-02 2001-03-15 Heterocyclic compounds for therapeutic use

Publications (2)

Publication Number Publication Date
US20010047023A1 true US20010047023A1 (en) 2001-11-29
US6403629B2 US6403629B2 (en) 2002-06-11

Family

ID=25201453

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/809,485 Expired - Fee Related US6403629B2 (en) 2000-05-02 2001-03-15 Heterocyclic compounds for therapeutic use

Country Status (4)

Country Link
US (1) US6403629B2 (en)
EP (1) EP1377289A4 (en)
AU (1) AU2002309243A1 (en)
WO (1) WO2002074235A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027201A1 (en) * 2005-07-29 2007-02-01 Wyeth Use of progesterone receptor modulators
US20070027125A1 (en) * 2005-07-29 2007-02-01 Wyeth Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015316A1 (en) * 1993-11-30 1995-06-08 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
AU6269496A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations
JP2002514640A (en) * 1998-05-14 2002-05-21 ジー・ディー・サール・アンド・カンパニー 1,5-Diaryl-substituted pyrazoles as p38 kinase inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027201A1 (en) * 2005-07-29 2007-02-01 Wyeth Use of progesterone receptor modulators
US20070027125A1 (en) * 2005-07-29 2007-02-01 Wyeth Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof
US7297713B2 (en) 2005-07-29 2007-11-20 Wyeth Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof
US20080064673A1 (en) * 2005-07-29 2008-03-13 Wyeth Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof
US7652062B2 (en) 2005-07-29 2010-01-26 Wyeth Llc Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof

Also Published As

Publication number Publication date
EP1377289A2 (en) 2004-01-07
AU2002309243A1 (en) 2002-10-03
EP1377289A4 (en) 2008-09-10
WO2002074235A2 (en) 2002-09-26
WO2002074235A3 (en) 2003-08-28
US6403629B2 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
US6803380B1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
JP3996656B2 (en) 4- (Arylaminomethylene) -2,4-dihydro-3-pyrazolone compounds
JP4488663B2 (en) Thrombopoietin mimetic
AU771668B2 (en) 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
KR100345942B1 (en) 1-phenylpyrazole compounds or optical isomers therof, and pharmaceutical compositions for treatment of hyperuricacidemia and gout comprising said compounds as effective ingredient
Abdel-Aziz et al. Synthesis of N-benzenesulfonamide-1H-pyrazoles bearing arylsulfonyl moiety: novel celecoxib analogs as potent anti-inflammatory agents
SK281468B6 (en) Heterocyclic aromatic oxazole compounds, intermediates for their preparation, pharmaceutical preparations, cyclooxygenase inhibitors and anti-inflammatory agents
JPH09505829A (en) 1,4,5-Triphenylpyrazolyl compounds for treating inflammation and inflammation-related disorders
EA014693B1 (en) Therapeutically active compounds
US20070066651A1 (en) Pyrazoline derivatives useful for the treatment of cancer
JP2009530401A (en) Phenolic hydrazone macrophage metastasis inhibitor
JP4828142B2 (en) Novel fused pyrazolyl compounds
WO1998022442A2 (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds and their use as cyclooxygenase i (cox 1) inhibitors
JP2001519343A (en) Novel 3,4-diarylthiazolin-2-one or 2-thione derivative, its preparation method and therapeutic use
JP2021519797A (en) Compositions and Methods for Treating Renal Injury
JPS62108814A (en) Inhibitor against formation of peroxide lipide
US6403629B2 (en) Heterocyclic compounds for therapeutic use
US20040097539A1 (en) Hsp inductor
US7723370B2 (en) 1, 2-diaryl pyrazoles useful as analgetic and antiinflammatory agents
JP4759207B2 (en) 1- (Benzothiazol-2-yl) pyrazole derivatives and COX-2 inhibitors containing the same
JP2003300880A (en) Apoptosis inhibitor
KR100824715B1 (en) A pyrazole derivative, preparation thereof and selective cyclooxygenase-1 inhibitor comprising the same
JPS5846090A (en) Furano-chromone derivatives, manufacture and medicine containing them
JP2004123700A (en) Peroxynitrite-eliminating agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: J.B. CHEMICAL AND PHARMACEUTICALS LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHRIKHANDE, ATUL ANANT;DOSHI, MADHUKANT MANSUKHLAL;MODY, SHIRISH BHAGWANLAL;REEL/FRAME:011624/0862

Effective date: 20010228

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140611